I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.


Paul Heath

Dr Catherine Cosgrove

Tatiana Munera Huertas

Jennifer Pearce

Hana Tabusa

Eva Galiza

Shari Sapuan

Alberto San Francisco Ramos

Shamez Ladhani

Natalina Sutton

Simon Drysdale

Hazel Fofie

Zsofia Danos

David Smith

Fran Mabesa

Luis de Luna

Nicole Branch

Elena Stefanova

Vanessa Greening

Shehnaz Athaide

Naomi Hayward

Suzannah Wright

Jonathan Lewis-Bridgeman

Hannah Sharp

Uzma Khan

Shivani Patel

Cecilia Hultin

Sinduja Sivarajan

Thahmena Miah

Emma Eccleston

Sana Ibrahim

Director
Paul Heath
Paul Heath is a Professor and Honorary Consultant in Paediatric Infectious Diseases at St George’s University Hospitals NHS Foundation Trust and St George’s, University of London, where he co-leads the Paediatric Infectious Diseases Research Group and is the Director of the Vaccine Institute. His particular research interests are in the epidemiology of vaccine preventable diseases, in clinical vaccine trials, particularly in at-risk groups and in perinatal infections. He coordinates a European neonatal infection surveillance network (neonIN) and the UK Paediatric Vaccine Group (UKPVG), and other recent work includes national surveillance on neonatal meningitis, neonatal GBS and Listeria infections, maternal immunisation trials, studies of different vaccine schedules in preterm infants and COVID-19 vaccine trials (Phase I-III). He is Chair of the Research Committee of the European Society of Paediatric Infectious Diseases, Section Editor of the Pediatric Infectious Diseases Journal (maternal & neonatal), Clinical Lead for Children’s research for South London and a member of the WHO GBS Surveillance Technical Working Group.
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S; 2019nCoV-302 Study Group. N Engl J Med. 2021 Jun 30:NEJMoa2107659. doi: 10.1056/NEJMoa2107659. Vergnano S, Godbole G, Simbo A, Smith-Palmer A, Cormican M, Anthony M, Heath PT. Arch Dis Child. 2021 May 13:archdischild-2021-321602. doi: 10.1136/archdischild-2021-321602. Ding Y, Wang Y, Hsia Y, Russell N, Heath PT. Emerg Infect Dis. 2020 Nov;26(11):2651-2659. doi: 10.3201/eid2611.181414. Khalil A, Kalafat E, Benlioglu C, O’Brien P, Morris E, Draycott T, Thangaratinam S, Le Doare K, Heath P, Ladhani S, von Dadelszen P, Magee LA. EClinicalMedicine. 2020 Aug;25:100446. doi: 10.1016/j.eclinm.2020.100446. Epub 2020 Jul 3.PMID: 32838230 Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.PMID: 32702298
Email:pheath@sgul.ac.uk
Secretary Phone:020 8725 3262

Co-Director
Dr Catherine Cosgrove
Dr Catherine Cosgrove is Infectious Diseases and Acute Physician who trained in London at King’s College Hospital, with her specialist training at St George’s University Hospitals Foundation Trust and the Hospital for Tropical Diseases. She has extensive clinical experience working in the UK and abroad, in district general hospitals and large tertiary referral hospitals.
Catherine completed her PhD in vaccinology at the University of London. She has been Chief Investigator and Principal Investigator on a large range of phase 1 to Phase 4 clinical vaccine studies, in addition to other studies looking at diagnosis in TB, genetic studies in TB and HIV, patient perceptions and knowledge of TB, HIV and vaccines. She is committed to improving knowledge of infectious diseases, with a special interest in TB and HIV and uptake of vaccines in under-represented groups. She provides teaching, training, question and answer sessions for a wide range of audiences, including secondary schools with a view to widening participation in medicine.
Clinically her NHS practice is in TB, HIV, Acute Medicine. It includes acute on calls and Infectious diseases inpatients, outpatients and on calls. The infectious diseases ward at St George’s is a dedicated 18 bedded negative pressure Infectious diseases ward which is part of the National Infectious Diseases network. She provides specialist care and advice on Infectious Diseases across South West London, Surrey and Sussex.
Catherine has many leadership roles including South West Sector Lead for Tuberculosis, member of the PanLondon Clinical Working Group for Tuberculosis and SW London lead for ambulatory care overseeing a major million pound expansion of the ambulatory care unit and an increase to 25% of the acute intake being ambulated.
Catherine is involved with many charities for children with special needs and is a keen swimmer and cyclist with a love of cooking.
Email:ccosgrov@sgul.ac.uk

Operations Manager
Tatiana Munera Huertas
Tatiana (Taty) is the Operations Manager responsible for the strategic planning and overall direction of the group. She is a group leader with more than 10 years’ experience coordinating and managing a large international portfolio of research studies, including observational studies and phase I-IV adult, maternal, paediatric and neonatal clinical trials funded by national and international agencies and commercial companies. She is a microbiologist by training and joined the PIDRG in 2010 after finishing her PhD in Molecular Biology at Imperial College London.
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial – PubMed (nih.gov)
- Mutational analysis of the Aspergillus ambient pH receptor PalH underscores its potential as a target for antifungal compounds – PubMed (nih.gov)
- Refining the pH response in Aspergillus nidulans: a modulatory triad involving PacX, a novel zinc binuclear cluster protein – PubMed (nih.gov)
- Further characterization of the signaling proteolysis step in the Aspergillus nidulans pH signal transduction pathway – PubMed (nih.gov)
- Establishment of the ambient pH signaling complex in Aspergillus nidulans: PalI assists plasma membrane localization of PalH – PubMed (nih.gov)
Email:tmunerah@sgul.ac.uk
Phone:+44 (0) 2087255214

Senior Research Nurse
Jennifer Pearce
Jenny joined the team in January 2018 and has since become the senior research nurse. Currently heavily involved in Covid-19 vaccine trials and is involved in set up, recruitment, and follow up of participants. Her role also includes looking after the nursing team and helping to mentor junior staff starting their journey into research, this includes teaching infant/paediatric venepuncture and vaccination.
Email:jpearce@sgul.ac.uk
Ext:Ext 2316/3887/2780

Vaccine Programme Manager
Hana Tabusa
Hana has worked in the field of clinical trials since 2013. She has worked on studies ranging from commercially sponsored studies to investigator-led studies funded by the NIHR, EU and charities. She has experience of coordinating research studies from the application process, through to set up, recruitment and analysis, close out and archiving. Hana spent 4 years working at the Bristol Trials Centre managing studies in colorectal disease, cardiac surgery and ophthalmology. She returned to the Paediatric Infectious Diseases Research Group in December 2020.
Email:Htabusa@sgul.ac.uk

Senior Clinical Research Fellow
Eva Galiza
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S; 2019nCoV-302 Study Group.
N Engl J Med. 2021 Jun 30:NEJMoa2107659. doi: 10.1056/NEJMoa2107659. Online ahead of print. PMID: 34192426
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, Blane B, Bonsall D, Cicconi P, Charlton S, Clutterbuck EA, Collins AM, Cox T, Darton TC, Dold C, Douglas AD, Duncan CJA, Ewer KJ, Flaxman AL, Faust SN, Ferreira DM, Feng S, Finn A, Folegatti PM, Fuskova M, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hallis B, Heath PT, Hay J, Hill HC, Jenkin D, Kerridge S, Lazarus R, Libri V, Lillie PJ, Ludden C, Marchevsky NG, Minassian AM, McGregor AC, Mujadidi YF, Phillips DJ, Plested E, Pollock KM, Robinson H, Smith A, Song R, Snape MD, Sutherland RK, Thomson EC, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Williams CJ, Hill AVS, Lambe T, Gilbert SC, Voysey M, Ramasamy MN, Pollard AJ; COVID-19 Genomics UK consortium; AMPHEUS Project; Oxford COVID-19 Vaccine Trial Group.
Lancet. 2021 Apr 10;397(10282):1351-1362. doi: 10.1016/S0140-6736(21)00628-0. Epub 2021 Mar 30. PMID: 33798499
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group.
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19. PMID: 33617777
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group.
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. PMID: 33306989
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group.
Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. PMID: 32702298

Paediatric Clinical Research Fellow
Shari Sapuan
Sapuan S, Kortsalioudaki C, Anthony M, Chang J, Embleton ND, Geethanath RM et al. Neonatal
Listeriosis in the UK 2004-2014. Journal of Infection. 2016 Nov 17. Available
from: 10.1016/j.jinf.2016.11.007
Email:ssapuan@sgul.ac.uk

Adult Clinical Research Fellow
Alberto San Francisco Ramos
Alberto is an Infectious Diseases and Microbiology Specialist Registrar with an interest in Global Health and Emerging Infectious Diseases. Alberto joined SGVI as part of a research placement in September 2020 and is currently working as an Adult clinical research fellow in several COVID-19 vaccine trials. He is the lead fellow for the COM-COV and COM-COV2 studies looking at heterologous COVID-19 vaccine schedules.
Alberto is also involved in studying vaccine responses in immunocompromised patients. He is investigating immune responses to meningococcal vaccinations (MenACWY and MenB) in HIV+ patients (ProPositive and Propositive follow-up trials), as well as the immunogenicity of COVID-19 vaccination in Tuberous Sclerosis Complex patients taking mTor inhibitor therapy.
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021 Jun 30. doi: https://doi.org/10.1056/NEJMoa2107659.
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. The Lancet Volume 397, Isuue 10289, P2043-2046, May 29, 2021. Part of Com-COV Study group. https://doi.org/10.1016/S0140-6736(21)01115-6
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet Volume 397, Issue 10282, 10–16 April 2021, Pages 1351-1362. Part of Oxford Vaccine Group. https://doi.org/10.1016/S0140-6736(21)00628-0
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 6-12 March; 397(10277): 881–891. Part of Oxford Vaccine Group. https://doi.org/10.1016/S0140-6736(21)00432-3
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2020 Dec 8;S0140-6736(20)32661-1. Part of Oxford Vaccine Group. https://doi.org/10.1016/S0140-6736(20)32661-1
Email:asanfran@sgul.ac.uk


Paediatric Clinical Research Fellow
Natalina Sutton
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S; 2019nCoV-302 Study Group. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021 Jun 30
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98.
Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 Mar 6;397(10277):881-891.
Davies S, Sutton N, Blackstock S, Gormley S, Hoggart CJ, Levin M, Herberg JA. Predicting IVIG resistance in UK Kawasaki disease. Arch Dis Child. 2015 Apr;100(4):366-8.
Email:nsutton@sgul.ac.uk

Consultant in Paediatric Infectious Diseases
Simon Drysdale
- Drysdale SB, Kelly DF, Morgan M, Peto T, Crook D, Matthews PC, Walker TM. Case Report: Disseminated, rifampicin resistant Mycobacterium bovis (BCG) infection in an immunocompromised child. Wellcome Open Research 2020; 5: 242.
- Lin GL, Golubchik T, Drysdale S, O’Connor D, Jefferies K, Brown A, de Cesare M, Bonsall D, Ansari MA, Aerssens J, Bont L, Openshaw P, Martinón-Torres F, Bowden R, Pollard AJ. Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants. J Infect Dis. 2020 Jul 23:jiaa448. doi: 10.1093/infdis/jiaa448. Online ahead of print.
- Jefferies K, Drysdale SB, Robinson H, Clutterbuck EA, Blackwell L, McGinley J, Lin GL, Galal U, Nair H, Aerssens J, Öner D, Langedijk A, Bont L, Wildenbeest JG, Martinon-Torres F, Rodríguez-Tenreiro Sánchez C, Nadel S, Openshaw P, Thwaites R, Widjojoatmodjo M, Zhang L, Nguyen TL, Giaquinto C, Giordano G, Baraldi E, Pollard AJ; Respiratory Syncytial Virus Consortium in Europe (RESCEU) Investigators. Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU). J Infect Dis. 2020 Aug 14:jiaa239. doi: 10.1093/infdis/jiaa239. Online ahead of print.
- Öner D, Drysdale SB, McPherson C, Lin GL, Janet S, Broad J, Pollard AJ, Aerssens J; RESCEU Investigators. Biomarkers for Disease Severity in Children Infected With Respiratory Syncytial Virus: A Systematic Literature Review. J Infect Dis. 2020 Aug 14:jiaa208. doi: 10.1093/infdis/jiaa208. Online ahead of print.
- Sande CJ, Njunge JM, Mwongeli Ngoi J, Mutunga MN, Chege T, Gicheru ET, Gardiner EM, Gwela A, Green CA, Drysdale SB, Berkley JA, Nokes J, Pollard AJ. Airway response to respiratory syncytial virus has incidental antibacterial effects. Nat Commun. 2019;10(1):2218. doi: 10.1038/s41467-019-10222-z.
Email:simon.drysdale@nhs.net

Paediatric Clinical Research Fellow
Hazel Fofie
Dr Hazel Fofie is a clinical research fellow and paediatric registrar based in London with interests in international child health, acute paediatrics, paediatric infectious diseases and health inequalities. She trained at St George’s, University of London and completed an intercalated BSc in Global Health at Kings College London. She has attained membership with the Royal College of Paediatrics and Child Health and has obtained the professional diploma in tropical medicine and hygiene.
She takes part in ongoing paediatric research activity run by St George’s Vaccine George’s Vaccine Institute and the Paediatric Infectious Diseases Research Group (PIDRG), an in particular the day to day organisation and running of the RSV Vaccine Studies and some COVID-19 vaccine trials.
Her most recent publication is a commentary in EClinical Medicine Series published by The Lancet, Ethnic minority and migrant underrepresentation in Covid-19 research: Causes and solutions.
Etti M, Fofie H, Razai M, Crawshaw A, Hargreaves S, Goldsmith L. Ethnic minority and migrant underrepresentation in Covid-19 research: Causes and solutions. EClinical Medicine. 2021 [Available from: http://www.sciencedirect.com/science/article/pii/S2589537021001838
Email:hfofie@sgul.ac.uk

Paediatric Clinical Research Fellow
Zsofia Danos
A Folyovich, I Vastagh, A Kéri, A Majoros, KL Kovács, A Ajtay, Zs Laki, B Gunda, K Erdei, L Lenti, Zs Dános, D Bereczki Living standard is related to microregional differences in stroke characteristics in Central Europe: the Budapest Districts 8-12 Project Int J Public Health DOI 10.1007/s00038-015-0674-y 2015
D. Bereczki, A. Ajtay, A. Majoros, Z. Dános, L. Lenti, K. Erdei, L.K. Kovács, B. Gunda, Z. Laki, A. Kéri, I, Vastagh, A. Folyovich Gender difference in the living standard on 3-year stroke fatality: the Budapest District 8-12 project.
Email:zdanos@sgul.ac.uk

Adult Clinical Research Fellow
David Smith
Smith, D., & Gill, D. (2021). Antivirals against SARS-CoV-2 by autumn?. BMJ, 373, n1215. doi:10.1136/bmj.n1215
Burgess, S., Smith, D., Kenyon, J. C., & Gill, D. (2020). Lightening the viral load to lessen covid-19 severity.. BMJ, 371, m4763. doi:10.1136/bmj.m4763
Patterson, B., Smith, D., Telford, A., Tana, A., Johnstone, D., Davidson, R., & Martineau, A. R. (2020). Vitamin D deficiency predicts latent TB reactivation independent of preventive therapy: a longitudinal study.. Int J Tuberc Lung Dis, 24(9), 916-921. doi:10.5588/ijtld.19.0605
Email:dasmith@sgul.ac.uk

Paediatric Research Nurse
Fran Mabesa
Fran’s background has been neonatal nursing. Fran joined the team in March 2018 where she has been working as part of Paediatric Infectious disease Research Group as well as Vaccine Institute department. Fran has worked on paediatric and COVID 19 vaccine trials.
National Health Training College; Diploma in General Nursing Diploma in Midwifery.
Middlesex University; BSc in Occupational Safety, Health and Environment.
Email:fmabesa@sgul.ac.uk

Infectious Diseases Research Nurse
Luis de Luna
Luis joined the Vaccine Institute in 2021 and is one of the research nurses supporting the COVID-19 trials and other studies carried out at St George’s.
Email:delunag@sgul.ac.uk

Paediatric Research Nurse
Nicole Branch
I have worked with the PIDRG since January 2020 and moved across full-time in December 2020. I have previously worked in paediatric surgery and paediatric A&E at Birmingham Children’s Hospital and St George’s before transferring across into research. I am currently working on COVID-19 vaccine trials and DIAMONDS Search, a paediatric observational study.
Before re-training to become a paediatric nurse, I graduated in French and Spanish and was working as an English language teacher in France and Spain.
Email:nbranch@sgul.ac.uk

Paediatric Research Nurse
Elena Stefanova
I have graduated as a paediatric nurse in 1998, have been practising in the UK since 2011. Joined the research team at St George’s Hospital, London in March 2017.
Since then and currently have been involved in various studies-neurology, neurosurgery, gastroenterology, infectious diseases, with main focus on antimicrobial resistance and vaccine studies.
Email:estefano@sgul.ac.uk
Office Number:0208 725 2780

Research Midwife
Vanessa Greening
Vanessa is a research midwife within the Paediatric Infectious Diseases Group within the Vaccine Institute, leading on studies that involve surveillance, interventions or treatments in pregnancy.
Prior to her role in research, Vanessa worked as a clinical midwife in multiple maternity units across the UK and abroad. She trained in Southampton graduating in 2010.
Email:vgreenin@sgul.ac.uk

Paediatric Research Nurse
Shehnaz Athaide
I have been working in Vaccine Institute as an Adult Clinical Research Nurse since April 2019 till date. My work mainly focuses on collecting data for our current Adult research studies, recruiting participants, conducting clinical appointments, taking study related clinical samples, processing them and recording data on a secure system. I enjoy my work while being a part of vaccine research team at St. Georges University of London and NHS trust.
Email:sathaide@sgul.ac.uk


Project Manager
Suzannah Wright
Suzannah is a Project Manager with over five years’ experience working in clinical trials. She primarily supports the paediatric vaccine studies, working closely with the multidisciplinary team at St George’s Vaccine Institute to set up and co-ordinate the clinical trials.
Email:wright@sgul.ac.uk

Project Officer
Jonathan Lewis-Bridgeman
Jonathan is currently working as Project Officer within the P.I.D.R.G team located at St. George’s University Hospital. He oversees the coordination of clinical trial studies through setup, recruitment, data management and collection, finance and budgets; through to close-out.
Email:jlewis-b@sgul.ac.uk

Project Officer
Hannah Sharp
Hannah has been working in the PIDRG since November 2020, primarily supporting the administrative challenges of the COVID-19 vaccine trials (such as Novavax and COV002) and paediatric trials.
In her role as a Project Officer Hannah manages the Com-COV and Com-COV2 studies, investigating the immunogenicity and reactogenicity of mixed vaccine schedules.
Initial results from this study were recently published in the Lancet
Hannah also currently coordinates two maternal studies, the Pfizer COVID Vaccine Maternal Study and the Pfizer GBS6 Study, as well as KD-CAAP, investigating treatments for Kawasaki disease.
Email:hsharp@sgul.ac.uk

Project Manager
Uzma Khan
Uzma is a MSc graduate in Preventive Cardiology and clinical trials from Imperial College University of London with experience in clinical trials over 4 years. She has been working with the PIDRG since 2018 and is responsible for effective project management of a variety of phase 1 – 4 clinical trials, ensuring they are delivered on time, within budget and in compliance with regulatory requirement. She has worked on studies that focused on group B meningococcal vaccines, whooping cough vaccines as well as RSV vaccines and has coordinated multi-centre studies. Recently, she has been coordinating the COVID19 phase 2/3 vaccine trial at St George’s University London and has completed her PRINCE2 certification.
Email:uzkhan@sgul.ac.uk

Project Officer
Shivani Patel
I am a graduate of the University of Brighton, where I completed my Bsc in Pharmaceutical Chemistry. I have 5 years of experience working within healthcare, and a year within clinical trials specifically. I joined the PIDRG team in November 2020 during the COVID-19 pandemic. Since joining I have been involved in the set up and day to day running of the Oxford COVID-19 vaccine trials for both adults and paediatrics. I am also currently involved with multiple RSV studies and also the paediatric observational study DIAMONDS.
Email:shpatel@sgul.ac.uk

Paediatric Clinical Research Nurse
Cecilia Hultin
Cecilia qualified as a nurse in Helsinki, Finland and spent her first 5 years working in Paediatric Oncology and stem cell transplantation.
Cecilia joined the team in 2019 and has been working on paediatric vaccine trials and infectious disease studies. She is currently involved with leading on the COVID-19 vaccine trials at St George’s.
Phone:|

Project Manager
Sinduja Sivarajan
Sinduja (Sindu) is a Clinical Trial Manager at St George’s University, working within the Centre of Neonatal and Paediatric Infection. Her passion for research led her to pursue a Masters degree at William Harvey Research Institute, QMUL in 2017 and was awarded a Distinction. She has over 4 years’ experience in the field of clinical trials and has worked on many studies, including renal and oncology trials. Currently, Sinduja is working on the Preg-CoV trial looking at COVID-19 vaccines in pregnancy.

Paediatric Research Nurse
Thahmena Miah
Thahmena’s background has been in paediatric surgery, which included a wide range of specialities, including ENT, trauma and orthopaedics, gastroenterology and neurology and neurosciences. Thahmena began working with the vaccine institute, initially to help with the Covid-19 studies and officially became part of the team in 2021. Thahmena is currently involved with paediatric studies involved in chicken pox, invasive aspergillosis / mucormycosis and TB.
Email:tmiah@sgul.ac.uk

Research Midwife
Emma Eccleston
Emma is a Research Midwife at the Vaccine Institute. She is currently researching COVID-19 vaccines in pregnancy and leading on a Maternal Group B Streptococcus vaccine study.
Prior to her role as a Research Midwife, Emma worked as a Senior Clinical Midwife and the Lead Immunisation Midwife at a South West London NHS Trust.
Email:eecclest@sgul.ac.uk

Clinical Trial Manager
Sana Ibrahim
Sana is a Clinical Trial Manager at St George’s University of London, working within the Centre of Neonatal and Paediatric Infection. She has graduated with a BSc in Pharmacology and Physiology at the University of Kent and Greenwich and is currently completing her MSc in Drug Development Science at King’s College London. Sana is working on a number of ward studies and facilitating the set up and coordination of multi-centre studies such as NeonIN, NeoAMRO and cCMV registry.
Email:sibrahim@sgul.ac.uk